338 related articles for article (PubMed ID: 14664902)
1. ADMA and oxidative stress.
Sydow K; Münzel T
Atheroscler Suppl; 2003 Dec; 4(4):41-51. PubMed ID: 14664902
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.
Böger RH; Vallance P; Cooke JP
Atheroscler Suppl; 2003 Dec; 4(4):1-3. PubMed ID: 14664896
[No Abstract] [Full Text] [Related]
3. The DDAH/ADMA/NOS pathway.
Tran CT; Leiper JM; Vallance P
Atheroscler Suppl; 2003 Dec; 4(4):33-40. PubMed ID: 14664901
[TBL] [Abstract][Full Text] [Related]
4. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.
Böger RH; Zoccali C
Atheroscler Suppl; 2003 Dec; 4(4):23-8. PubMed ID: 14664899
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
6. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
Weis M; Kledal TN; Lin KY; Panchal SN; Gao SZ; Valantine HA; Mocarski ES; Cooke JP
Circulation; 2004 Feb; 109(4):500-5. PubMed ID: 14732750
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
[TBL] [Abstract][Full Text] [Related]
9. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.
Lentz SR; Rodionov RN; Dayal S
Atheroscler Suppl; 2003 Dec; 4(4):61-5. PubMed ID: 14664904
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
Böger RH
Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
[TBL] [Abstract][Full Text] [Related]
13. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
14. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
15. ADMA: its role in vascular disease.
Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
[TBL] [Abstract][Full Text] [Related]
16. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis.
Antoniades C; Shirodaria C; Leeson P; Antonopoulos A; Warrick N; Van-Assche T; Cunnington C; Tousoulis D; Pillai R; Ratnatunga C; Stefanadis C; Channon KM
Eur Heart J; 2009 May; 30(9):1142-50. PubMed ID: 19297385
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
Sydow K; Mondon CE; Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
[TBL] [Abstract][Full Text] [Related]
18. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine (ADMA) elevation and arginase up-regulation contribute to endothelial dysfunction related to insulin resistance in rats and morbidly obese humans.
El Assar M; Angulo J; Santos-Ruiz M; Ruiz de Adana JC; Pindado ML; Sánchez-Ferrer A; Hernández A; Rodríguez-Mañas L
J Physiol; 2016 Jun; 594(11):3045-60. PubMed ID: 26840628
[TBL] [Abstract][Full Text] [Related]
20. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
Toutouzas K; Riga M; Stefanadi E; Stefanadis C
Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]